Encompass Health (NYSE:EHC) Stock Rating Lowered by StockNews.com

Encompass Health (NYSE:EHC) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a report issued on Friday.

Several other research analysts also recently weighed in on the stock. Barclays upped their price objective on shares of Encompass Health from $116.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday. William Blair restated an “outperform” rating on shares of Encompass Health in a report on Friday. Truist Financial reiterated a “buy” rating and issued a $116.00 target price (up previously from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. KeyCorp upped their target price on shares of Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 29th. Finally, Royal Bank of Canada upped their target price on shares of Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $107.33.

Encompass Health Stock Up 1.3 %

Shares of Encompass Health stock traded up $1.26 during trading on Friday, reaching $99.86. 1,202,546 shares of the company traded hands, compared to its average volume of 666,318. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04. Encompass Health has a 1-year low of $72.37 and a 1-year high of $104.55. The company has a 50 day moving average price of $96.28 and a 200-day moving average price of $95.19. The firm has a market capitalization of $10.06 billion, a PE ratio of 24.12, a P/E/G ratio of 1.18 and a beta of 0.90.

Encompass Health (NYSE:EHC) last released its earnings results on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.12. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. As a group, equities research analysts expect that Encompass Health will post 4.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Encompass Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new position in Encompass Health during the fourth quarter valued at $77,944,000. Point72 Asset Management L.P. raised its position in shares of Encompass Health by 2,458.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company’s stock worth $83,990,000 after purchasing an additional 835,135 shares during the last quarter. Jennison Associates LLC purchased a new position in shares of Encompass Health in the 4th quarter worth about $52,094,000. abrdn plc purchased a new position in shares of Encompass Health in the 4th quarter worth about $17,846,000. Finally, Thrivent Financial for Lutherans raised its position in shares of Encompass Health by 26.0% in the 3rd quarter. Thrivent Financial for Lutherans now owns 760,496 shares of the company’s stock worth $73,494,000 after purchasing an additional 156,938 shares during the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.